Cream for frontal fibrosing alopecia
Treatments studied
Part of Skin clinical trials.
This trial tests a cream called delgocitinib for a type of hair loss that affects the front of the scalp and eyebrows. The cream may help reduce redness and scaling and potentially slow or stop the hair loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of frontal fibrosing alopecia with moderate to severe redness or scaling in a target area.
- You are willing to keep the same hair style and hair products during the trial, and avoid weaves or extensions.
- You have not used certain hair-growth supplements or treatments (like biotin, Nutrafol, or Viviscal) in the last 4 weeks.
- You have not used topical treatments for your condition (like steroid creams or JAK inhibitors) in the last 2 weeks.
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called deucravacitinib for people with scarring hair loss (frontal fibrosing alopecia or central centrifugal cicatricial alopecia). It aims to see if the drug can reduce inflammation and stop or slow hair loss.
This study tests whether laser therapy can help treat small bumps (papules) that appear on the face in people with frontal fibrosing alopecia, a type of hair loss. If you have these bumps and are generally healthy, you may be able to join.
This study tests an oral medication called delgocitinib, which targets certain enzymes linked to inflammation, in people with central centrifugal cicatricial alopecia (CCCA) or lichen planopilaris (LPP). It aims to see if the drug is safe and if it changes biomarkers (biological signals) related to these conditions.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
This Phase 2 trial tests dupilumab (an injection medicine) to regrow hair in people with alopecia areata, a condition where the immune system attacks hair follicles. It may help by reducing the immune-related inflammation linked to hair loss.
This trial tests a cream called delgocitinib for adults with lichen sclerosus in the genital area. It aims to see if the cream can safely and effectively reduce symptoms over 52 weeks.
Hear when a new Frontal Fibrosing Alopecia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.